This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Optimizing the Management of LDL-Cholesterol for Improved Patient Outcomes: Maintaining Cardiovascular Health in Patients with Hypercholesterolemia

Optimizing the Management of LDL-Cholesterol for Improved Patient Outcomes: Maintaining Cardiovascular Health in Patients with Hypercholesterolemia

Format

Expert Perspective

Time to Complete

1 hour

Released

September 22, 2016

Expires

September 22, 2017
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Jointly provided by Postgraduate Institute for Medicine and Consultants in Medical Education (CiME)

Commercial Supporter

This activity is supported by an independent educational grant from Amgen Inc.

Program Description

Currently in the US, one-third of all deaths occur as a result of cardiovascular disease (CVD). Despite many clinical studies into hypercholesterolemia and dyslipidemia, only low-density lipoprotein cholesterol (LDL-C) has been definitely established as a robust surrogate parameter for atherosclerotic CVD (ASCVD), and today a low percentage of patients at high risk of ASCVD are attaining the LDL-C goal of at least a 50% reduction recommended by the ACC/AHA, NLA and other national and international guidelines. Supplementary to diet and lifestyle changes, the increasing number of pharmacologic agents available with differing mechanisms of action means that clinicians have a better armamentarium of options to help patients achieve LDL-C goals and have a positive impact on cardiovascular disease risk. This activity uses a combination of case-based and didactic methodologies along with supporting audio insights to assist learners in developing management plans that maximize reduction of both LDL-C, and ASCVD risk, in their patients.

Intended Audience

This activity has been designed to meet the educational needs of primary care physicians and other health care clinicians involved in the treatment of patients with hypercholesterolemia and dyslipidemias.

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Describe pathophysiologic pathways of LDL-C metabolism, and targets for pharmacologic therapy
  • Compare the efficacy and safety of statins, ezetimibe and PCSK-9 inhibitors in lowering LDL-C
  • Identify patients who are candidates for intensification of LDL-C therapy, including dosage optimization, improving adherence, and combination regimens
  • Individualize treatment plans to increase the population of patients achieving LDL-C goals

Conflict Of Interest Disclosure Policy

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Eliot A. Brinton, MD, FAHA, FNLA
Immediate Past-President, American Board of Clinical Lipidology
President, Utah Lipid Center
Salt Lake City, Utah

Dr. Brinton discloses the following:
Advisory Board (for scientific information): Alexion, Amarin, Amgen, Aralez, Kowa, Merck, PTS Diagnostics, Regeneron, Sanofi

Speakers’ Bureau: Alexion, Amarin, Amgen, AstraZeneca, Genzyme, Janssen, Kowa, Merck, Regeneron, Sanofi, Takeda

Planner and Manager Disclosures

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

CiME manager, Chris Blagden, PhD, hereby states that he or his spouse do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Consultants in Medical Education (CiME). The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period September 13, 2016 through September 12, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity.

To obtain credit, a score of 75% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please visit: www.pimed.com

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue